A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 2006-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the efficacy and safety of MabThera/Rituxan (rituximab) in treatment-naive patients with non-bulky follicular non-Hodgkin's lymphoma. The anticipated time on study treatment is 3 months.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Rituximab

Criteria

Inclusion Criteria:

• Adult patients 18-75 years of age

• Newly diagnosed non-bulky follicular non-Hodgkin's lymphoma

• >/=1 measurable lesion

• No prior treatment (no corticosteroids or radiotherapy)

Exclusion Criteria:

• Transformed follicular lymphoma

• Cerebral or meningeal lymphomaotus localization

• Uncontrolled concurrent infection